- Advertisement -
- Advertisement -
- Advertisement -

Find a job

Subscribe for free

All things Pharma

EC approves combination ACS treatment

The European Commission has approved Sanofi-aventis and Bristol-Myers Squibb’s dual antiplatelet combination tablet DuoPlavin/DuoCover (clopidogrel and acetylsalicylic acid).

The combination treatment is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA).

It is a fixed-dose treatment for:

· non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention

· ST segment elevation acute myocardial infarction ((STEMI) in medically treated patients eligible for thrombolytic therapy.

Robust evidence from large clinical studies has led to the approval and use of Plavix in

combination with acetylsalicylic acid. The new formulation has the advantage of reducing the daily pill burden for patients.

- Advertisement -
Previous article
Next article

MORE FROM AUTHOR

- Advertisement -

LATEST POSTS

Subscribe

Sign up to receive our digital newsletter, for all the essential headlines, Jobs of the Week and thought-provoking features.

Claim my free subscription